Author:
Hunsicker Lawrence G.,Atkins Robert C.,Lewis Julia B.,Braden Gregory,Champion De Crespigny Paul J.,Deferrari Giacomo,Drury Paul,Locatelli Francesco,Wiegmann Thomas B.,Lewis Edmund J.
Reference7 articles.
1. The irbesartan type II diabetic nephropathy trial: Study design and baseline patient characteristics. For the Collaborative Study Group;Rodby;Nephrol Dial Transplant,2000
2. Renoprotective effect of the angiotensin-receptor antagonist irbersartan in patients with nephropathy due to type 2 diabetes;Lewis;N Engl J Med,2001
3. Irbesartan Diabetic Nephropathy Trial. Collaborative Study Group. Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy;Berl;Ann Int Med,2003
4. Impact of angiotensin receptor blockade with irbesartan on renal function at different systolic blood pressure (SBP) levels in type 2 diabetic nephropathy;Pohl;J Am Soc Nephrol,2002
5. Effect of baseline proteinuria and change in proteinuria with treatment on the risk of renal endpoints in the Irbesartan in Diabetic Nephropathy Trial (IDNT);Atkins;J Am Soc Nephrol,2002
Cited by
45 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献